Semax
ACTH(4-7)PGP — Cognitive & Neuroprotective Peptide
What is Semax?
Semax is a heptapeptide analog of ACTH developed in Russia and approved there for stroke, TBI, and cognitive impairment. It increases BDNF, NGF, and VEGF in the brain and is widely used in the biohacking community for cognitive enhancement and neuroprotection. Intranasal administration allows rapid CNS delivery.
Semax increases BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), and VEGF in the brain — key molecules for neuronal survival, plasticity, and learning. It also modulates dopaminergic and serotonergic systems and exhibits potent anti-inflammatory effects in the CNS.
Research Evidence
Russian clinical trials show improved neurological outcomes in stroke and TBI patients. Approved as a prescription drug in Russia for these indications.
Preclinical studies consistently demonstrate BDNF upregulation and improved learning, memory, and anxiety measures in animal models.
Community use for attention and working memory is widespread. Plausible mechanism via dopaminergic modulation. Limited controlled human trials for this application.
Evidence grades: Gold = RCT human data · Silver = multiple animal studies, consistent · Bronze = limited or preliminary
Dosing Protocols
Reconstitution Guide
| Vial Size | BAC Water | Concentration | Target draw |
|---|---|---|---|
| 5 mg | 5 ml | 1 mg/ml | 300mcg = 30 units |
| 10 mg | 10 ml | 1 mg/ml | 300mcg = 30 units |
Frequently Asked Questions
What does Semax do?
Semax increases BDNF and NGF in the brain, supporting neuronal health, learning, and memory. Users report improved focus, working memory, and mental clarity. It has clinical approval in Russia for stroke recovery and cognitive impairment.
Is intranasal or SubQ Semax better?
Intranasal is preferred for cognitive applications — it allows direct CNS penetration via the olfactory route, bypassing the blood-brain barrier. SubQ has more predictable systemic dosing but lower CNS bioavailability.
References
- [1]Lebedeva IS, Panikratova YR, Sokolov OY, et al. Effects of Semax on the Default Mode Network of the Brain. Bull Exp Biol Med. 2018;165(5):653-656.
- [2]Shadrina MI, Dolotov OV, Khudoleeva OA, et al. Neuroprotective effect of Semax in rat model of focal cerebral ischemia. Bull Exp Biol Med. 2001;131(5):470-472.
This profile was prepared using AI-assisted research synthesis. Citations are provided where applicable — verify with primary sources before clinical application.
Share this article